Research ExplorerPublicationsDiabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzie...

Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen

Standard

Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen. / Meinertz, T; Sydow, K.

In: HERZ, Vol. 39, No. 3, 05.2014, p. 320-324.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Meinertz, T & Sydow, K 2014, 'Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen', HERZ, vol. 39, no. 3, pp. 320-324. https://doi.org/10.1007/s00059-014-4085-2

APA

Meinertz, T., & Sydow, K. (2014). Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen. HERZ, 39(3), 320-324. https://doi.org/10.1007/s00059-014-4085-2

Vancouver

Meinertz T, Sydow K. Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen. HERZ. 2014 May;39(3):320-324. https://doi.org/10.1007/s00059-014-4085-2

Bibtex

@article{078e5409353c475b8c26fb46cd8ecb07,
title = "Diabetes mellitus--Risikofaktor f{\"u}r Vorhofflimmern. Potenzielle therapeutische Implikationen",
abstract = "The relationship between atrial fibrillation and diabetes mellitus type 2 is controversial, and various studies have demonstrated conflicting results. However, the majority of larger prospective studies published during recent years demonstrated a positive correlation. After multivariate adjustment diabetes increased the risk for atrial fibrillation at least two fold. This combination is associated with substantially increased risks of death and cardiovascular events (stroke and heart failure). Atrial fibrillation in patients with diabetes mellitus type 2 identifies individuals who are likely to obtain greater benefits from glycemic control and anticoagulants as well as antihypertensive therapy. ",
keywords = "Anticoagulants/therapeutic use, Antihypertensive Agents/therapeutic use, Atrial Fibrillation/mortality, Causality, Comorbidity, Diabetes Mellitus, Type 2/mortality, Humans, Hypoglycemic Agents/therapeutic use, Incidence, Risk Factors, Survival Rate",
author = "T Meinertz and K Sydow",
year = "2014",
month = may,
doi = "10.1007/s00059-014-4085-2",
language = "Deutsch",
volume = "39",
pages = "320--324",
journal = "HERZ",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "3",

}

RIS

TY - JOUR

T1 - Diabetes mellitus--Risikofaktor für Vorhofflimmern. Potenzielle therapeutische Implikationen

AU - Meinertz, T

AU - Sydow, K

PY - 2014/5

Y1 - 2014/5

N2 - The relationship between atrial fibrillation and diabetes mellitus type 2 is controversial, and various studies have demonstrated conflicting results. However, the majority of larger prospective studies published during recent years demonstrated a positive correlation. After multivariate adjustment diabetes increased the risk for atrial fibrillation at least two fold. This combination is associated with substantially increased risks of death and cardiovascular events (stroke and heart failure). Atrial fibrillation in patients with diabetes mellitus type 2 identifies individuals who are likely to obtain greater benefits from glycemic control and anticoagulants as well as antihypertensive therapy.

AB - The relationship between atrial fibrillation and diabetes mellitus type 2 is controversial, and various studies have demonstrated conflicting results. However, the majority of larger prospective studies published during recent years demonstrated a positive correlation. After multivariate adjustment diabetes increased the risk for atrial fibrillation at least two fold. This combination is associated with substantially increased risks of death and cardiovascular events (stroke and heart failure). Atrial fibrillation in patients with diabetes mellitus type 2 identifies individuals who are likely to obtain greater benefits from glycemic control and anticoagulants as well as antihypertensive therapy.

KW - Anticoagulants/therapeutic use

KW - Antihypertensive Agents/therapeutic use

KW - Atrial Fibrillation/mortality

KW - Causality

KW - Comorbidity

KW - Diabetes Mellitus, Type 2/mortality

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

KW - Incidence

KW - Risk Factors

KW - Survival Rate

U2 - 10.1007/s00059-014-4085-2

DO - 10.1007/s00059-014-4085-2

M3 - SCORING: Zeitschriftenaufsatz

C2 - 24699792

VL - 39

SP - 320

EP - 324

JO - HERZ

JF - HERZ

SN - 0340-9937

IS - 3

ER -